Form 4: Opaleye Management Inc. Increases Stake in Eton Pharmaceuticals, Inc. Through Recent Stock Purchases

Opaleye Management Inc., a significant shareholder of Eton Pharmaceuticals, Inc., has increased its holdings through a series of open market purchases in early October 2024.

Summary

• Opaleye Management Inc. has reported several transactions involving the purchase of Eton Pharmaceuticals, Inc. (ETON) common stock.
• These transactions occurred between October 4, 2024, and October 8, 2024.
• The purchases were made both directly by Opaleye, L.P. and through a separately managed account.
• On October 4, 2024, Opaleye, L.P. purchased 15,000 shares at a weighted average price of $6.771 per share, and the managed account purchased 1,852 shares at the same price.
• On October 7, 2024, Opaleye, L.P. purchased 10,000 shares at a weighted average price of $7.2235 per share, and the managed account purchased 1,248 shares at the same price.
• On October 8, 2024, the managed account purchased 30,000 shares at a weighted average price of $7.0292 per share, and an additional 3,970 shares at the same price.
• Following these transactions, Opaleye, L.P. beneficially owns 2,760,000 shares, and the managed account beneficially owns 82,070 shares.
• Opaleye Management Inc. disclaims beneficial ownership of these shares except to the extent of its pecuniary interest.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The increased stake suggests confidence, but it's a routine filing.

Positives

• Opaleye Management Inc.'s increased investment in Eton Pharmaceuticals could be interpreted as a positive signal about the company's prospects.
• The purchases demonstrate confidence from a significant shareholder.

Risks

• The Form 4 filing itself doesn't inherently indicate risks, but it's important to monitor Opaleye's future transactions and overall ownership trends.
• A decrease in ownership in the future could be a negative signal.

Industry Context

Form 4 filings are a routine part of the regulatory landscape for publicly traded companies, providing transparency into the trading activities of insiders and significant shareholders.

Stakeholder Impact

• The increased stake could positively influence shareholder confidence.
• The purchases could have a minor impact on the stock price in the short term.

Key Dates